Indium -111 pentetreotide

FDA label, Curium US LLC, effective 2022-02-21. Full label on DailyMed

Patient handout

Looking up MedlinePlus…

From MedlinePlus, U.S. National Library of Medicine

Quoted from the FDA label. Product labels differ by manufacturer and change over time; confirm against the label for the product you are using.

Dosing in kidney impairment

Table 4. Estimated Absorbed Radiation Doses after Intravenous Administration of Indium In 111 PentetreotideAssumes 4.8 hour voiding interval and International Commission on Radiological Protection (ICRP) 30 model for the gastrointestinal tract calculations.to a 70 kg Patient
PLANAR SPECT
Organ mGy/111 MBq rads/3 mCi mGy/222 MBq rads/6 mCi
Kidneys 54.16 5.42 108.32 10.83
Liver 12.15 1.22 24.31 2.43
Spleen 73.86 7.39 147.73 14.77
Uterus 6.34 0.63 12.67 1.27
Ovaries 4.89 0.49 9.79 0.98
Testes 2.90 0.29 5.80 0.58
Red Marrow 3.46 0.35 6.91 0.69
Urinary Bladder Wall 30.24 3.02 60.48 6.05
GI Tract
Stomach Wall 5.67 0.57 11.34 1.13
Small Intestine 4.78 0.48 9.56 0.96
Upper Large Intestine 5.80 0.58 11.59 1.16
Lower Large Intestine 7.73 0.77 15.46 1.55
Adrenals 7.55 0.76 15.11 1.51
Thyroid 7.43 0.74 14.86 1.49
mSv/111 MBq rem/3 mCi mSv/222 MBq rem/6 mCi
Effective DoseEstimated according to ICRP Publication 53.Equivalent 13.03 1.30 26.06 2.61

Preparation and administration

Prepare this dose

Your numbers for indium -111 pentetreotide. Take vial strength, diluent, and limits from the label below.

Basis

Enter a dose to see draw volume, final concentration, and rates.

The recommended intravenous dose for SPECT imaging is 222 MBq (6 mCi) of Indium In 111 Pentetreotide Injection. The dose should be confirmed by a suitably calibrated radioactivity ionization chamber immediately before administration. As with all intravenously administered products, Octreoscan should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Do not administer Octreoscan in TPN solutions or through the same intravenous line. Radiation Dosimetry The estimated radiation doses Values listed include a correction for a maximum of 0.1% indium In-114m radiocontaminant at calibration. to the average adult (70 kg) from intravenous administration of 111 MBq (3 mCi) and 222 MBq (6 mCi) are presented in Table 4.

Contraindications

None known.

Pregnancy and lactation

Pregnancy

Pregnancy Animal reproduction studies have not been conducted with indium In 111 pentetreotide. It is not known whether indium In 111 pentetreotide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Therefore, Indium In 111 Pentetreotide Injection should not be administered to a pregnant woman unless the potential benefit justifies the potential risk to the fetus.

Lactation

Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Indium In 111 Pentetreotide Injection is administered to a nursing woman.

For breastfeeding, also see LactMed (National Library of Medicine), which summarizes milk levels and infant effects.

Supply and cost

Drug shortage status

Loading
Source: FDA Drug Shortages Database via openFDA

Recalls (last 24 months)

Loading
Source: FDA Enforcement Reports via openFDAFDA recalls and safety alerts

Therapeutic equivalence (Orange Book)

Loading
Source: FDA Orange Book data filesSearch the Orange Book

Price ladder

Not the price at the counter
Loading

These are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.

VA Federal Supply ScheduleCMS NADACMedicare Part D plan filesMedicaid State Drug Utilization Data

Calculators for indium -111 pentetreotide